Humana price target lowered to $310 from $356 at Barclays

Barclays analyst Andrew Mok lowered the firm’s price target on Humana to $310 from $356 and keeps an Equal Weight rating on the shares. The final Medicare Advantage rate for 2025 from the Centers for Medicare & Medicaid Services showed no improvement from the proposed rule and came in well below the low-end of investor expectations, the analyst tells investors in a research note.